Clinical Trial Update: TMC114-C213: A Phase II Randomized, Controlled, Partially Blinded Trial to Investigate Dose-response of TMC114/RTV in 3-class-experienced HIV-1 Infected Patients, Followed by an Open-label Period on the Recommended Dose of TMC114/RTV. [Phase 2]

View source ↗

Summary

This Phase II trial update reports the completion of a randomized, partially blinded dose-response study of darunavir/ritonavir in 3-class experienced HIV-1 pat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Norvir (ritonavir)
• PREZISTA (darunavir)

Snippet

Sponsor: Tibotec Pharmaceuticals, Ireland | Conditions: HIV | Phase 2 | Status: COMPLETED